Tika R. Malla

University Of Oxford 12 Mansfield Road Oxford OX1 3TA UK
Oxford, ENG OX13TA, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

RaPID discovery of cell-permeable helical peptide inhibitors con-taining cyclic β-amino acids against SARS-CoV-2 main protease.

RaPID discovery of cell-permeable helical peptide inhibitors con-taining cyclic β-amino acids against SARS-CoV-2 main protease.

Journal: RSC chemical biology

Published: February 02, 2025

Cyclic β2,3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease.

Cyclic β2,3-amino acids improve the serum stability of macrocyclic peptide inhibitors targeting the SARS-CoV-2 main protease.

Journal: Bulletin of the Chemical Society of Japan

Published: December 27, 2023

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors.

Journal: Science (New York, N.Y.)

Published: November 09, 2023

Accelerating drug target inhibitor discovery with a deep generative foundation model.

Accelerating drug target inhibitor discovery with a deep generative foundation model.

Journal: Science advances

Published: June 21, 2023

Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.

Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine.

Journal: Journal of medicinal chemistry

Published: February 09, 2023

Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.

Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine.

Journal: Journal of medicinal chemistry

Published: May 13, 2022

In vitro selection of macrocyclic peptide inhibitors containing cyclic γ2,4-amino acids targeting the SARS-CoV-2 main protease.

In vitro selection of macrocyclic peptide inhibitors containing cyclic γ2,4-amino acids targeting the SARS-CoV-2 main protease.

Journal: Nature chemistry

Published: April 05, 2022

Studies on the Reactions of Biapenem with VIM Metallo β-Lactamases and the Serine β-Lactamase KPC-2.

Studies on the Reactions of Biapenem with VIM Metallo β-Lactamases and the Serine β-Lactamase KPC-2.

Journal: Antibiotics (Basel, Switzerland)

Published: January 25, 2022

Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.

Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.

Journal: ChemMedChem

Published: January 07, 2022

Expanding the Repertoire of Low-Molecular-Weight Pentafluorosulfanyl-Substituted Scaffolds.

Expanding the Repertoire of Low-Molecular-Weight Pentafluorosulfanyl-Substituted Scaffolds.

Journal: ChemMedChem

Published: October 01, 2021

Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.

Publisher Correction: Bispecific repurposed medicines targeting the viral and immunological arms of COVID-19.

Journal: Scientific reports

Published: September 29, 2021

Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-CoV-2 Main Protease.

Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-CoV-2 Main Protease.

Journal: ChemMedChem

Published: September 03, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026